Remove Cardiology Remove Clinical Trials Remove Regulation
article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog

Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field. In October, FDA announced seven new clinical trial grants awarded in fiscal year (FY) 2024 – including one for a Phase 3 trial – totaling $17.2

article thumbnail

How the Ukrainian clinical trial industry is overcoming disruption

Pharmaceutical Technology

Clinical trials were thrown into turmoil on the morning of 24 February 2022, along with every aspect of life in Ukraine. In July, approximately a third of companies had paused a trial in the country. By August, 28 foreign-sponsored, multi-country trials were affected, almost half with sites in Ukraine and Russia. [1].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

LIB Therapeutics’ Cholesterol Lowering Med Lerodalcibep Receives FDA BLA Acceptance

XTalks

For instance, in the LIBerate-HeFH trial in patients with HeFH, the treatment led to mean placebo-adjusted LDL-C reductions of 65% at 24 weeks, with approximately 68% of patients achieving LDL-C reductions of 50% or more, meeting European Society of Cardiology guideline-recommended targets.

article thumbnail

Obicetrapib Lowers LDL-C as Monotherapy and with Ezetimibe in Phase III Trials

XTalks

Menarini Group has announced positive topline data from the Phase III BROADWAY and TANDEM clinical trials, evaluating obicetrapib and the fixed-dose combination of obicetrapib with ezetimibe. Unlike CETP inhibitors, PCSK9 inhibitors block a protein that regulates cholesterol levels.

Trials 52
article thumbnail

Tryngolza (Olezarsen) Becomes First FDA-Approved Drug for Familial Chylomicronemia Syndrome

XTalks

Tryngolza works by targeting a protein in the liver, apoC-III, which regulates triglyceride metabolism. In clinical trials, it showed up to an 86 percent reduction in triglyceride levels. By lowering its production, Tryngolza significantly reduces triglyceride levels in the blood.

article thumbnail

BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M

Delveinsight

The decision gave Bayer complete control of BlueRock’s cell therapy pipeline, headed by DA01 and spanning various diseases in the neurology , cardiology , and immunology categories. CMAs work as a new approach to stimulate mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy.

article thumbnail

Vericiguat approved in Japan to treat patients with chronic heart failure

The Pharma Data

Bayer is proud of the approval of vericiguat in Japan and the contribution it has shown in clinical trials.”. About Cardiology at Bayer Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments.